Log in

ASX:OSLOncosil Medical Stock Price, Forecast & News

+0.01 (+9.09 %)
(As of 05/13/2020)
Today's Range
Now: A$0.12
50-Day Range
MA: A$0.12
52-Week Range
Now: A$0.12
Volume2.17 million shs
Average VolumeN/A
Market Capitalization$81.24 million
P/E RatioN/A
Dividend YieldN/A
OncoSil Medical Limited, a medical device company, focuses on the development of localized treatments for cancer in Australia. Its lead product is OncoSil, a brachytherapy device comprising OncoSil Phosphorous-32 Microparticles and OncoSil Diluent, which implants a pre-determined dose of beta radiation emitting isotope directly into cancerous tissue for the treatment of pancreatic and liver cancer. The company was formerly known as NeuroDiscovery Limited and changed its name to OncoSil Medical Limited in June 2013. OncoSil Medical Limited is headquartered in North Sydney, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.65 out of 5 stars

Industry, Sector and Symbol

Industry Diagnostics & Research
Phone61 2 9223 3344



Sales & Book Value

Annual Sales$2.98 million
Cash FlowA$0.01 per share
Book ValueA$0.01 per share



Market Cap$81.24 million
Next Earnings DateN/A
OptionableNot Optionable

Receive OSL News and Ratings via Email

Sign-up to receive the latest news and ratings for OSL and its competitors with MarketBeat's FREE daily newsletter.

Oncosil Medical (ASX:OSL) Frequently Asked Questions

How has Oncosil Medical's stock been impacted by COVID-19 (Coronavirus)?

Oncosil Medical's stock was trading at A$0.11 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, OSL stock has increased by 9.1% and is now trading at A$0.12. View which stocks have been most impacted by Coronavirus.

Has Oncosil Medical been receiving favorable news coverage?

News headlines about OSL stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Oncosil Medical earned a daily sentiment score of -1.2 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about Oncosil Medical.

Who are some of Oncosil Medical's key competitors?

What other stocks do shareholders of Oncosil Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncosil Medical investors own include WiseTech Global (WTC), Twitter (TWTR), Qube (QUB), Procter & Gamble (PG), Charter Hall Education Trust (CQE), Blackmores (BKL) and APA Group (APA).

Who are Oncosil Medical's key executives?

Oncosil Medical's management team includes the following people:
  • Mr. Daniel Kenny B.Sc., CEO, MD & Exec. Director
  • Mr. Tom Milicevic B.Comm, FCPA, MBA MGSM, CFO & Company Sec. (Age 47)
  • Mr. Michael Warrener, Global Sales & Marketing Director
  • Dr. Ashish Soman, Chief Medical Officer
  • Dr. David C. James, Global Head of Manufacturing Operations

What is Oncosil Medical's stock symbol?

Oncosil Medical trades on the ASX under the ticker symbol "OSL."

What is Oncosil Medical's stock price today?

One share of OSL stock can currently be purchased for approximately A$0.12.

How big of a company is Oncosil Medical?

Oncosil Medical has a market capitalization of $81.24 million and generates $2.98 million in revenue each year.

What is Oncosil Medical's official website?

The official website for Oncosil Medical is www.oncosil.com.au.

How can I contact Oncosil Medical?

The company can be reached via phone at 61 2 9223 3344.

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.